Laurus Labs Ltd

Laurus Labs Ltd is in the Pharmaceuticals sector with the Market Capitalization of worth Rs. 37508.48 crores, it is incorporated in the year 2005. It features consolidated sales of Rs. 1220.60 crores in June 2021. The company is also listed in the Bombay Stock Exchange (BSE) with the code 540222 and additionally listed in the National Stock Exchange (NSE) with the code LAURUSLABS.

Laurus Labs is one of the top pharmaceuticals companies in the country, holding a leadership position in research & development and manufacturing of generic APIs. The company is also working with several top pharmaceuticals companies worldwide for research & development with a primary focus on anti-retroviral, Hepatitis C, and Oncology drugs. The company also owns around 155 patents. The headquarters of Laurus labs are situated in the city of Hyderabad, while its manufacturing plants are located in Visakhapatnam, Hyderabad, and Bengaluru. Laurus Labs has also received several approvals from major regulatory medical bodies worldwide, such as WHO, USFDA, KFDA, MHRA, etc. In March’20, Laurus Labs received approval from USFDA for hydroxychloroquine tablets, which were initially used to treat the COVID-19 patients. The promoters within the company currently hold 53.56% of the stake in the company, while the Foreign Institutional Investors (FII) and Domestic Institutional Investors (DII) hold 6.65% and 3.44% of the stake. The balance of 36.35% is by others (retail investors).

In June 2021, quarterly net sales were Rs. 1,220.6 crores, which has increased by approximately 25.78% from Rs. 970.4 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 222.08 crores, which has grown by 39.87% from a net profit of Rs. 158.78 crores in June 2020. In June 2021, operating profit was reported at Rs. 1,032.11 crores, which is also increased by 25.79% as compared to an operating profit of Rs. 820.49 crores for the quarter ending in June 2020. From Rs. 2.97 in June 2020, the EPS of Laurus Labs has grown to just Rs. 4.14 per share in June 2021. LAURUSLABS’s stock closed at Rs. 689.35 on 16th August’2021 (NSE) and has returned 86.97% in the last six months and 234.49% within the last year.

Laurus Labs share price as on 28 Mar 2025 is Rs. 615.3. Over the past 6 months, the Laurus Labs share price has increased by 32.47% and in the last one year, it has increased by 56.88%. The 52-week low for Laurus Labs share price was Rs. 385.45 and 52-week high was Rs. 646.2.

Laurus Labs Ltd is in the Pharmaceuticals sector with the Market Capitalization of worth Rs. 37508.48 crores, it is incorporated in the year 2005. It features consolidated sales of Rs. 1220.60 crores in June 2021. The company is also listed in the Bombay Stock Exchange (BSE) with the code 540222 and additionally listed in the National Stock Exchange (NSE) with the code LAURUSLABS.

Laurus Labs is one of the top pharmaceuticals companies in the country, holding a leadership position in research & development and manufacturing of generic APIs. The company is also working with several top pharmaceuticals companies worldwide for research & development with a primary focus on anti-retroviral, Hepatitis C, and Oncology drugs. The company also owns around 155 patents. The headquarters of Laurus labs are situated in the city of Hyderabad, while its manufacturing plants are located in Visakhapatnam, Hyderabad, and Bengaluru. Laurus Labs has also received several approvals from major regulatory medical bodies worldwide, such as WHO, USFDA, KFDA, MHRA, etc. In March’20, Laurus Labs received approval from USFDA for hydroxychloroquine tablets, which were initially used to treat the COVID-19 patients. The promoters within the company currently hold 53.56% of the stake in the company, while the Foreign Institutional Investors (FII) and Domestic Institutional Investors (DII) hold 6.65% and 3.44% of the stake. The balance of 36.35% is by others (retail investors).

In June 2021, quarterly net sales were Rs. 1,220.6 crores, which has increased by approximately 25.78% from Rs. 970.4 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 222.08 crores, which has grown by 39.87% from a net profit of Rs. 158.78 crores in June 2020. In June 2021, operating profit was reported at Rs. 1,032.11 crores, which is also increased by 25.79% as compared to an operating profit of Rs. 820.49 crores for the quarter ending in June 2020. From Rs. 2.97 in June 2020, the EPS of Laurus Labs has grown to just Rs. 4.14 per share in June 2021. LAURUSLABS’s stock closed at Rs. 689.35 on 16th August’2021 (NSE) and has returned 86.97% in the last six months and 234.49% within the last year.

Laurus Labs share price as on 28 Mar 2025 is Rs. 615.3. Over the past 6 months, the Laurus Labs share price has increased by 32.47% and in the last one year, it has increased by 56.88%. The 52-week low for Laurus Labs share price was Rs. 385.45 and 52-week high was Rs. 646.2.